Recombinant factor VIIa - A new option in intractable bleeding?

International Journal of Intensive Care

Volumn 10, Issue 2, 2003, Pages 73-80

  Heuer, Lars ^a,b   Blumenberg, D ^a  

^a Intensive Care Unit   (Germany)

^b Andreas Bannowsky Ltd   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FONDAPARINUX; HEPARIN; LEPIRUDIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN;

BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HEMOPHILIA; HUMAN; LIVER DISEASE; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM;

EID: 0345401246     PISSN: 13502794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Weiss HJ, Lages B. Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 1988; 42: 629-635.
2. Hoffmann M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
3. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331-334.
4. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841.
5. Berkner K, Busby S, Davie E et al. Isolation and expression of cDNAs encoding human factor VII. Quant Biol 1986; 51: 531-541.
6. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-547.
7. Rock G, Wells P. New concepts in coagulation. Crit Rev Clin Lab Scienc 1997; 34: 475-501.
8. Doughty HA, Northeast A, Sklair L et al. The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery. Blood Coagul Fibrinol 1995; 6: 125-128.
9. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-778.
10. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-539.
11. Johannessen M, Andreasen RB, Nordfang O. Decline of factor VIII and factor IX inhibitors during long-term treatment with NovoSeven. Blood Coagul Fibrinolysis 2000; 11: 239-242.
12. Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia A with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 1463-1467.
13. Schulman S, Bech Jensen M, Varon D. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost 1996; 75: 432.
14. Scharrer I, Großmann R. Erworbene Hemmkörperhämophilie. Anaesthesist 2000; 49: 49-34.
15. Crowther MA, Julian J, McCarty D et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000; 356: 1551-1557.
16. Erhardtsen E, Nony P, Dechavanne P, Efrench P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven®) in healthy volunteers receiving acennocoumarol to an international normalized ratio above 2.0. Blood Coagul Fibrinol 1998; 9: 741-748.
17. Sørensen B, Johansen P, Sørensen JC, Ingerslev J. Emergency use of NovoSeven® in life-threatening haemorrhagia in patients on oral anticoagulation therapy: Monitoring of efficacy by a novel whole blood TEF principle from which velocity and acceleration profiles of clotting can be established. Presented at 6th Novo Nordisk Symposium on Treatment of Bleeding and Thrombotic Disorders. Copenhagen, 2001.
18. Abildgaard CF. Hazards of prothrombin-complex-concentrates in the treatment of hemophilia. N Engl J Med 1981; 305: 717-721.
19. Farred J, Walenga JM, Bender N et al. Bleeding effects of antithrombin drugs can be neutralized by activated FVIIa (NovoSeven®) and combination of other plasma derived products. Thromb Haemost 2001; 84: P2614.
20. Lewis B, O'Leary M, Vinh T. Successful use of rVIIa (NovoSeven) to reverse enoxaparin (levonox) overdose in an adult patient with intracranial bleeding. Thromb Haemost 2001; 84: P2633.
21. Heuer L, Denter M, Rehra N, Blumenberg D. Recombinant factor VIIa (rFVIIa) stops severe bleeding from abdominal wall haematoma induced by an overdose of heparin in a high-risk patient - case report. Br J Anaesth 2002; 89(Suppl): 19-20 (Abstract DS05).
22. Hows JM, Brozovic B. Platelet and granulocyte transfusions. BMJ 1990; 300: 520.
23. Révész T, Arets B, Bierings M, van den Bos C, Duval E. Recombinant factor VIIa in severe uremic bleeding. Thromb Haemost 1998; 80: 353.
24. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier Syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80: 352.
25. d'Orion R, Ménart C, Trzeciak MC et al. Use of recombinant factor VIIa in 3 patients with inherited Type I Glanzmann's Thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-647.
26. Ménart C, Treciak MC, Attali O, Négrier C. Continous infusion of NovoSeven® during colectomy in a Glanzmann thrombastenia patient with anti-glycoprotein IIb-IIIa antibody. Haemophilia 1998; 4: 499.
27. Meijer K, Sieders E, Slooff MJH, de Wolf JTH, van der Meer. Effective treatment of severe bleeding due to acquired thrombocytopathia by single dose administration of activated recombinant factor VII. Thromb Haemost 1998; 80: 204.
28. Kristensen J, Killander A, Hippe E et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopaenia. Haemostasis 1996; 26: 159-164.
29. Mammen EF. Coagulation defects in liver disease. Med Clin North Am 2000; 78: 545-554.
30. Abdelaal MA, Mazoki K, Khan Z, Sobhi EK. Successful cataract surgery under recombinant factor VIIa (NovoSeven) cover in a patient with coagulopathy due to chronic liver disease. Thromb Haemost 1997; 86: PS-348.
31. Papatheodoridis GV, Chung S, Keshav S, Pasi J, Burroughs AK. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol 1999; 31: 747-750.
32. Kositchaiwat C, Chuansumrit A. Experiences with recombinant factor VIIa for the prevention of bleeding in patients with chronic liver disease undergoing percutaneous liver biopsies and endoscopic retrograde cholangiopancreatography (ERCP). Thromb Haemost 2001; 86: 1125-1126.
33. Jeffers L, Bernstein DE, Erhardsten. The use of recombinant factor VIIa in laparoscopy liver biopsy: a pilot trial. Gastroenterology 1998; 114: L0275.
34. Bernstein DE, Jeffers L, Erhardtsen E et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997; 113: 1930-1937.
35. Kalincinski P, Kaminski A, Drewniak T et al. Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transpl Proc 1999; 31: 378-379.
36. Huth-Kühne A, Hampel H. Successful use of recombinant factor VIIa (rFVIIa) in a patient with impaired liver function and bleeding. J Hepatol 1999; 30: 200.
37. Hendriks HGD, Meijer K, de Wolf JTM. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2000; 71: 402-405.
38. Martinowitz U, Holcomb JB, Pusateri AE et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50: 721-729.
39. Kenet G. Recombinant FVIIa for profuse bleeding in trauma and surgery. Journal für Anaesthesie und Intensivbehandlung 2001; 3: 112-113.
40. Kenet G, Walden R, Eldad A, Martinowitz U. Surgical intervention failed to stop life-threatening bleeding caused by injury complicated by severe coagulopathy. Administration of recombinant factor VIIa immediately corrected the coagulopathy and stopped bleeding. Lancet 1999; 354: 1879.
41. Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-438.
42. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001; 36: 1081-1085.
43. Heuer L, Blumenberg D. Rekombinanter Faktor VIIa (NovoSeven)-Ein Überblick über aktuelle und mögliche zukünftige Indikationen. Der Anaesthesist 2002; 51: 388-399.
44. White B, McHale J, Ravi N et al. Successful use of recombinant FVIIa (NovoSeven®) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999; 107: 677-678.
45. Vlot AJ, Ton E, Mackaay AJC, Kramer MHH, Gaillard CAJM. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 2000; 108: 421-423.
46. Hendriks HGD, van der Maaten JM, de Wolf JTM, Waterbolk TW, Slooff MJ, van der Meer J. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93: 287-289.
47. Friederich PW, Geerdink MG, Spataro M et al. The effect of the administration of recombinant activated factor VII (NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coagul Fibrinolysis 2000; 11: S129-S132.
48. Al Douri M, Shafi T, Al Khudairi D et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinol 2000; 11: S121-S127.
49. Welty-Wolf KE, Carraway MS, Miller DL et al. Tissue factor blockade in experimental acute lung injury. Programme and abstracts from the 6th Novo Nordisk Symposium on the Treatment of Bleeding and Thrombotic Disorders. Copenhagen, 2001.
50. Doughty HA, Northeast A, Sklair L et al. The use of recombinant factor VIIa in a patient with acquired haemophilia A undergoing surgery. Blood Coagul Fibrinol 1995; 6: 125-128.
51. Product monograph NovoSeven. 2001.
52. Heuer L, Marré P, Blumenberg D. Recombinant factor VIIa-A cost-analysis in a single patient - first-line vs. ultima-ratio regimen. Proceedings of the 56th Postgraduate Assembly of the New York State Society of Anesthesiologists, 2002: P-9042.
53. Hedner U. NovoSeven® as a universal haemostatic agent. Blood Coagul Fibrinol 2000; 11: S107-S111.